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HERV-K in Cancer: The 
Phoenix of the Human 
Genome?
What is HERV-K?
Viruses have infected humans for millions of years, ever since the divergence from chimpanzees. 
Some viral infections are short-term, such as influenza, while others cause longer, more serious 
infections. A prime example of the latter is human immunodeficiency virus (HIV). This kind of virus is 
known as a retrovirus; these viruses enter cells and insert their genes into human DNA. The natural 
processes in which our cells create proteins from genes occurs in these viruses too, producing 
copies of the virus which can infect more cells. If retroviruses infect germ cells and do not produce 
a sufficient viral infection, the virus may be passed on through generations (Weiss, 2006). 
Retroviruses in which this occurs are called endogenous retroviruses, specifically HERVs in humans.
Many families of HERV exist, with HERV-K being the most active. HERV-K consists of genes 
required to create new viruses, flanked by long repeat sequences known as LTRs. However, most of 
the 127 different HERV-K insertions have been broken down so that only the LTRs remain (Pačes et 
al, 2002). As such, HERVs were long thought to be unimportant in disease, though work since 
suggests otherwise. 
HERV-K and Cancer
As the most active family, HERV-K has been theorised to play a role in many diseases (Hohn et al, 2013). In particular, HERV-K has been associated 
with several cancers, with multiple mechanisms linking the viruses to the disease. One such mechanism suggests that individual HERV-K insertions can 
aid the progression of cancer through their LTRs; these sequences can cause other genes that are nearby to produce more of their respective proteins 
(Cohen et al, 2009). If these genes, and therefore the proteins, are known to cause cancer, the presence of LTRs may also cause cancer. As such, LTRs 
may be described as “promoters” for cancer-related genes (termed proto-oncogenes).
Aim and Methods
The aim of the project was to see whether HERV-K insertions were associated with a risk in hepatocellular 
carcinoma (HCC), the most common form of liver cancer. To do this, I needed to search my 24 sample genomes for 
HERV-K insertions and compare their frequency compared to a general population using values derived from Wildschutte 
et al (2016). However, HERV-K is not the only insertional element, so many steps were required, as shown in the 
flowchart (figure 1). Firstly, all insertions were found; these were searched for the LTR of the youngest HERV-K (113) 
since this is the youngest and most intact LTR and is similar to all other HERV-K LTRs. The results were then studied to 
differentiate between HERV-K and another element that contains part of the LTR, called SVAs.
Discussion
The results obtained from this project 
oppose findings made by other studies 
which suggest that HERV-K may contribute 
to cancer. In fact, a study similar to this 
just last year announced results that 
contradict my own (Ma et al, 2016).
However, my results can be explained 
using one of the theories suggested to 
cause cancer; if HERV-K LTRs can act as 
promoters for proto-oncogenes, what says 
that they cannot also act as promoters for 
genes that prevent cancer?
If so, it would show the protective 
nature in a general population with 
increased amounts of HERV-K, although in 
this scenario it would require 
tumour-suppressor genes to be identified 
near insertions to see which in particular 
would work this way.
Either way, HERV-K insertions, 
previously thought to be broken pieces of 
junk DNA, may in fact rise from its ashes 
much like a phoenix, protecting us from 
cancer.
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Figures 1 and 2 are author's own work; phoenix icon taken from an open source website.
Results
When comparing the total number of each HERV-K insertion found in the genome samples, it was clear that the 
majority were far less common in HCC than in a general population. As seen in figure 2, all but one of the 36 HERV-K 
insertions were decreased in the cancer, 18 of which were significantly so (p < 0.05).
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Figure 1: A flowchart 
briefly showing how 
HERV-K insertions were 
found
Figure 2: The frequency of each HERV-K insertion observed in HCC 
patients (blue) and derived from a reference population (red)
